MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 12-23-2023
Aerie Pharmaceuticals Operating Income 2011-2026 | AERI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Aerie Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -46.4 M | -156 M | -187 M | -210 M | -146 M | -96.9 M | -75.1 M | -50 M | -22.2 M | -14.3 M | -14.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -14.2 M | -210 M | -92.5 M |
Quarterly Operating Income Aerie Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -26.7 M | -18.1 M | -33.6 M | - | -32.4 M | -31.5 M | -34.2 M | - | -33.6 M | -42.6 M | -43.9 M | - | -43.3 M | -46.1 M | -48.2 M | - | -61.3 M | -55.7 M | -40.8 M | - | -32.2 M | -27.8 M | -25.4 M | -28.8 M | -23.3 M | -22.7 M | -22.1 M | -20 M | -17.4 M | -18.1 M | -19.6 M | -16 M | -13.2 M | -11.8 M | -8.98 M | -16 M | -13.2 M | -11.8 M | -8.98 M | -6.75 M | -5.69 M | -5.11 M | -4.62 M | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -4.62 M | -61.3 M | -25.6 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M |  USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.2 | 0.42 % | $ 129 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-15.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 12.84 | 2.8 % | $ 657 M | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | $ 21.5 | -0.12 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
-34.4 M | $ 6.03 | -10.27 % | $ 374 M | USA |
 |
Harrow Health
HROW
|
431 K | $ 54.06 | 8.3 % | $ 1.76 B | USA |
 |
China Pharma Holdings
CPHI
|
-4.59 M | $ 1.23 | 1.65 % | $ 21.5 M |  China |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.7 | -1.74 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
963 M | $ 7.51 | 4.16 % | $ 2.74 B | Canada |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-55.6 M | - | - | $ 193 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 3.95 | -0.77 % | $ 55.5 M | USA |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 4.36 | -5.93 % | $ 574 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.72 | -1.41 % | $ 3.37 M | Canada |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 25.21 | 3.07 % | $ 1.17 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 3.73 | 2.46 % | $ 4.63 M | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 4.28 | -1.41 % | $ 86.3 M | Canada |
 |
Rockwell Medical
RMTI
|
-6.67 M | $ 0.98 | 13.92 % | $ 22.9 M | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
113 M | $ 14.36 | 3.42 % | $ 1.97 B | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
-36.9 M | $ 2.28 | 0.58 % | $ 308 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 1.11 | -4.31 % | $ 4.79 M | USA |
 |
Relmada Therapeutics
RLMD
|
-104 M | $ 4.11 | -6.06 % | $ 124 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-244 M | $ 9.62 | 5.25 % | $ 683 M | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-130 M | $ 5.33 | -2.14 % | $ 218 M | USA |
 |
SCYNEXIS
SCYX
|
72.7 M | $ 0.64 | -0.03 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 9.43 | -3.03 % | $ 5.83 B | Canada |
 |
TherapeuticsMD
TXMD
|
-8.52 M | $ 1.79 | 8.78 % | $ 18.7 M | USA |
 |
Zomedica Corp.
ZOM
|
-31.6 M | - | -0.21 % | $ 98 M | USA |